Discover
SABS
SAB Biotherapeutics, Inc.
3.51
1 x 3.45
1 x 3.37
bid
ask
+
0.01
0.29%
1 @ 07:30 PM
3.51 +0.00 (0.00%)
| Ytd | -6.15% | |
| 1y | 25.81% |
3.50
day range
3.56
1.95
52 week range
4.59
| Open | 3.50 | Prev Close | 3.50 | Low | 3.50 | High | 3.56 | Mkt Cap | 319.36M |
| Vol | 1.97M | Avg Vol | 502.83K | EPS | 0.24 | P/E | 14.63 | Forward P/E | -1.56 |
| Beta | 0.64 | Short Ratio | 1.22 | Inst. Own | 34.25% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-12 | 50-d Avg | 3.67 | 200-d Avg | 3.80 | 1yr Est | 12.40 |
| Income Statement | |||
| Operating Expenses | 23.38M | ||
| Research and Development Expense | 16.17M | ||
| Selling, General and Administrative Expense | 7.21M | ||
| Operating Income | -23.38M | ||
| Interest Expense | 62.00K | ||
| Net Income | -22.49M | ||
| Net Income Common Stock | -22.49M | ||
| Net Income Common Stock (USD) | -22.49M | ||
| Consolidated Income | -22.49M | ||
| Earnings per Basic Share | -0.28 | ||
| Earnings per Basic Share (USD) | -0.28 | ||
| Earnings per Diluted Share | -0.28 | ||
| Earning Before Interest & Taxes (EBIT) | -22.43M | ||
| Earning Before Interest & Taxes (USD) | -22.43M | ||
| Weighted Average Shares | 79.75M | ||
| Weighted Average Shares Diluted | 79.75M | ||
| Balance Sheet | |||
| Cash and Equivalents | 8.27M | ||
| Cash and Equivalents (USD) | 8.27M | ||
| Investments | 199.71M | ||
| Investments Current | 94.37M | ||
| Investments Non-Current | 105.35M | ||
| Current Assets | 107.94M | ||
| Property, Plant & Equipment Net | 19.58M | ||
| Total Assets | 238.21M | ||
| Debt Current | 641.00K | ||
| Total Debt | 5.13M | ||
| Current Liabilities | 11.71M | ||
| Debt Non-Current | 4.49M | ||
| Total Liabilities | 23.43M | ||
| Accumulated Retained Earnings (Deficit) | -152.25M | ||
| Accumulated Other Comprehensive Income | -930.00K | ||
| Shareholders Equity | 214.79M | ||
| Shareholders Equity (USD) | 214.79M | ||
| Assets Non-Current | 130.27M | ||
| Total Debt (USD) | 5.13M | ||
| Liabilities Non-Current | 11.72M | ||
| Trade and Non-Trade Payables | 3.86M | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 834.33K | ||
| Net Cash Flow from Financing | 2.36M | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | -12.25M | ||
| Capital Expenditure | -1.58M | ||
| Issuance (Purchase) of Equity Shares | 1.86M | ||
| Issuance (Repayment) of Debt Securities | -38.61K | ||
| Net Cash Flow from Investing | -4.88M | ||
| Net Cash Flow - Investment Acquisitions and Disposals | -3.30M | ||
| Net Cash Flow from Operations | -9.84M | ||
| Effect of Exchange Rate Changes on Cash | 107.27K | ||
| Share Based Compensation | 7.25M | ||